Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Harrow Inc. (HROW:NASDAQ), powered by AI.
Harrow Inc. is currently trading at $38.40. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Harrow Inc. on Alpha Lenz.
Harrow Inc.'s P/E ratio is -274.7.
“Harrow Inc. trades at a P/E of -274.7 (undervalued) with modest ROE of -8.4%. 3Y revenue CAGR of 45.4% highlights clear growth momentum.”
Ask for details →Harrow Inc. is a notable player in the healthcare and pharmaceutical sector, primarily focused on the development, production, and distribution of innovative medicines. The company's core competency is in ophthalmology, where it has established a reputation for delivering effective treatments for a range of eye conditions. Harrow Inc. not only pioneers in providing high-quality formulations but also commits to making these treatments affordable and accessible, aiming to address critical gaps in the market. Headquartered in the United States, Harrow Inc. operates a dynamic business model that includes both proprietary products and important generic formulations, catering to a diverse array of healthcare needs. Its significant role in the pharmaceutical industry is underscored by its impact on improving patient outcomes and its dedication to clinical excellence. By focusing on a vital area of healthcare, Harrow Inc. contributes to the overall enhancement of consumer quality of life and supports healthcare providers with essential, reliable products.
“Harrow Inc. trades at a P/E of -274.7 (undervalued) with modest ROE of -8.4%. 3Y revenue CAGR of 45.4% highlights clear growth momentum.”
Ask for details →Harrow Inc. (ticker: HROW) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 382 employees. Market cap is $1.4B.
The current price is $38.4 with a P/E ratio of -274.68x and P/B of 26.92x.
ROE is -8.42% and operating margin is 11.21%. Annual revenue is $272M.